Evidence map›Paper›PMID 37140873›Full record

Observational studyInternal and emergency medicine2023

Impact of SARS-CoV-2 infection in patients with hereditary hemorrhagic telangiectasia: epidemiological and clinical data from the comprehensive Italian retrospective multicenter study.

Patrizia Suppressa, Eugenia Maiorano, Eleonora Gaetani, Elina Matti, Gennaro Mariano Lenato, Ilaria Serio, Maristella Salvatora Masala, Giulio Cesare Passali, Maria Aguglia, Claudia Crocione and 8 more

Open access · hybridAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Internal and emergency medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 8 institutions in 1 country.

Patrizia Suppressa *"Frugoni" Internal Medicine and Geriatrics Unit, Centro Sovraziendale per le Malattie Rare, DIM-Interdisciplinary Department of Medicine, HHT Interdepartmental Center, VascERN HHT Reference Center, Policlinico Hospital, University of Bari, Bari, Italy. patrizia.suppressa@gmail.com.ORCID 0000-0002-3146-9173
Eugenia Maiorano *Department of Otorhinolaryngology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Eleonora GaetaniInternal Medicine and Gastroenterology Unit, Department of Medical and Surgical Sciences, Multidisciplinary Gemelli Group for HHT, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore School of Medicine, Rome, Italy.
Elina MattiDepartment of Otorhinolaryngology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Gennaro Mariano Lenato"Frugoni" Internal Medicine and Geriatrics Unit, Centro Sovraziendale per le Malattie Rare, DIM-Interdisciplinary Department of Medicine, HHT Interdepartmental Center, VascERN HHT Reference Center, Policlinico Hospital, University of Bari, Bari, Italy.
Ilaria SerioDivision of Internal Medicine, Department of Medical and Surgical Sciences, IRCCS Azienda Ospedaliero-Universitaria di Bologna, University of Bologna, Bologna, Italy.
Maristella Salvatora MasalaClinica Medica Unit, Sassari University Hospital, Sassari, Italy.
Giulio Cesare PassaliDivision of Otorhinolaryngology, Multidisciplinary Gemelli Group for HHT, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore School of Medicine, Rome, Italy.
Maria AgugliaClinical Pathology Unit, Vito Fazzi Hospital, Lecce, Italy.
Claudia CrocioneHHT Onlus Patient Association, Rome, Italy.
Pietro Luigi LopalcoDepartment of Biological and Environmental Science and Technologies, University of Salento, Lecce, Italy.
Francesca CaneschiUniversity of Pavia, Pavia, Italy.
Valeria MusellaClinical Epidemiology and Biometry Unit, Scientific Direction, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Annalisa De SilvestriClinical Epidemiology and Biometry Unit, Scientific Direction, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Giulia GambiniClinical Epidemiology and Biometry Unit, Scientific Direction, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Giuseppe SpinozziDepartment of Otorhinolaryngology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Carlo Sabbà"Frugoni" Internal Medicine and Geriatrics Unit, Centro Sovraziendale per le Malattie Rare, DIM-Interdisciplinary Department of Medicine, HHT Interdepartmental Center, VascERN HHT Reference Center, Policlinico Hospital, University of Bari, Bari, Italy.
Fabio PagellaDepartment of Otorhinolaryngology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Policlinico San Matteo Fondazione · ITUniversity of Bari Aldo Moro · ITAssociazione Italiana Vulvodinia Onlus · ITUniversità Cattolica del Sacro Cuore · ITUniversity of Pavia · ITUniversity of Bologna · ITUniversity of Salento · ITUniversity of Sassari · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rare Disease patients manifested high concern regarding the possible increased risk of severe outcomes and worsening of disease-specific clinical manifestation due to the impact of COVID-19. Our aim was to assess the prevalence, outcomes, and impact of COVID-19 in patients with a rare disease such as Hereditary Hemorrhagic Telangiectasia (HHT) in Italian population. A nationwide, multicentric, cross-sectional observational study was conducted on patients with HHT from five Italian HHT centers by online survey. The association between COVID-19-related signs and symptoms and nosebleeds worsening, the impact of personal protective equipment on nosebleeds pattern, and the relationship between the presence of visceral AVMs and severe outcomes were analyzed. Out of 605 total survey responses and eligible for analysis, 107 cases of COVID-19 were reported. A mild-course COVID-19 disease, not requiring hospitalization, was observed in 90.7% of patients, while the remaining eight cases needed hospitalization, two of them requiring intensive-care access. No fatal outcome was recorded and 79.3% of patients reported a complete recovery. No difference in infection risk and outcome between HHT patients and general population was evidenced. No significative interference of COVID-19 on HHT-related bleeding was found. The majority of patients received COVID-19 vaccination, with relevant impact on symptoms and need for hospitalization in case of infection. COVID-19 in HHT patients had an infection profile similar to the general population. COVID-19 course and outcome were independent from any specific HHT-related clinical features. Moreover, COVID-19 and anti-SARS-CoV-2 measures did not seem to affect significantly HHT-related bleeding profile.

Indexed as

COVID-19Telangiectasia, Hereditary HemorrhagicCOVID-19 VaccinesCross-Sectional StudiesEpistaxisHumansRare DiseasesSARS-CoV-2COVID-19 VaccinesArteriovenous malformationCOVID-19Hereditary hemorrhagic telangiectasiaRare diseasesSARS-CoV-2 infection

Identifiers

PMID37140873
PMCPMC10157588
OpenAlexW4368360343

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.